The price trend for P3 Health Partners Inc. (PIII) has been bearish lately and the stock has lost 13.1% over the past two weeks. However, the formation of a hammer chart pattern in its last trading session indicates that the stock could witness a trend reversal soon, as bulls might have gained significant control over the price to help it find support.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wal ...

P3 Health Partners Inc. (PIII) has been on a downward spiral lately with significant selling pressure. After declining 18.4% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting w ...

P3 Health Partners Inc. (PIII) came out with a quarterly loss of $6.28 per share versus the Zacks Consensus Estimate of a loss of $5. This compares to loss of $8 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -25.60%. A quarter ago, it was expected that this company would post a loss of $8.50 per share when it actually produced a loss of $16, delivering a surprise of -88.24%.Over the last four quarters, the company has not be ...

P3 Health Partners (PIII) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Company Participants Ryan Halsted - Managing DirectorAric Coffman - CEOLeif Pedersen - Chief Financial OfficerAmir Bacchus - Co-Founder and Chief Medical OfficerAaron Wukmir - Healthcare Equity Research AssociateJoshua Raskin - Partner - Managed Care & Providers Conference Call Participants Ryan Langston - Director & Senior Analyst - Healthcare Research Operator Good day, and welcome to the P3 Health Partners First Quarter twenty twent ...

P3 Health Partners (PIII) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Speaker0 Good day, and welcome to the P3 Health Partners First Quarter twenty twenty five Earnings Conference Call. All participants will be in listen only mode. Please note this event is being recorded. I would now like to turn the conference over to Brian Halstead. Please go ahead. Speaker1 Thank you, operator, and thank you for joining us today. Before we proceed with the call, I would like to remind everyone that certain statements ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) For the transition period from to Commission File Number: 001-40033 (State or other jurisdiction of incorporation or orga ...

P3 Health Partners Announces First Quarter 2025 Results Exhibit 99.1 Af irming 2025 guidance Management to Host Conference Call and Webcast May 15, 2025 at 4:30 PM ET HENDERSON, NV—May 15, 2025—P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financial results for the first quarter ended March 31, 2025, and affirmed its 2025 guidance. "Our physician-led care enablement model continues to differentia ...

P3 Health Partners Inc. (PIII) shares soared 8.9% in the last trading session to close at $9.79. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 5% gain over the past four weeks.P3 Health Partners recorded a strong price rise on investors’ optimism surrounding the company’s fourth quarter 2024 financial results. The company reported fourth quarter revenue of $371 million, a 7% increase year over year. The company reaffirmed its 2 ...

Medicare Market Overview - P3 Health Partners operates in the $1,029.8 billion Medicare market, covering approximately 68 million eligible lives as of November 2024[34]. - The Medicare Advantage (MA) market constitutes about 54% of the overall Medicare market, with nearly 33 million Medicare eligible lives in 2024[34]. - The penetration of MA plans among Medicare beneficiaries increased from 19% in 2007 to 54% in 2024, projected to reach 64% by 2034[43]. - The total addressable market for P3 is approximately 68 million Americans enrolled in traditional Medicare or MA, representing $1,030 billion of annual spend[46]. - The core addressable market for P3 is estimated to be over $300 billion, based on approximately 33 million Medicare Advantage members with an average spend of $1,000 per member per month[46]. Revenue and Financial Performance - Contracts with four health plans accounted for approximately 59% and 60% of P3's capitated revenue for the years ended December 31, 2024 and 2023, respectively[35]. - For the year ended December 31, 2024, the company incurred net losses of $310.4 million, resulting in an accumulated deficit of $503.2 million[128]. - The company expects to continue incurring operating losses and generating negative cash flows for the foreseeable future, indicating a need for additional funding in 2025[125]. - The company has issued an aggregate of 110.8 million shares of Class A common stock and warrants since December 2022, which may dilute ownership interests[132]. - The company is exploring raising additional capital through debt financing and equity issuances due to substantial doubt about its ability to continue as a going concern[126]. Operational Strategy and Growth - The company aims to expand its footprint in current markets like Arizona, California, Nevada, and Oregon, leveraging existing relationships with payors to increase membership[68]. - The company is focused on executing accretive acquisitions to grow its membership base, despite previous growth being primarily organic[71]. - The company maintains a disciplined growth strategy, periodically reviewing provider and payor contracts to exit underperforming ones and rationalize network costs[65]. - Future growth depends on the successful integration of new physician partners and expansion into new geographies, which may involve significant challenges[150]. Compliance and Regulatory Environment - The company operates under extensive regulatory requirements, including obtaining necessary licenses and maintaining compliance with federal and state regulations[88]. - P3's credentialing program ensures compliance with CMS and NCQA requirements, with providers recredentialed every three years[89]. - Non-compliance with healthcare laws could lead to significant penalties, including civil and criminal penalties, and loss of provider licenses[94]. - The Affordable Care Act has significantly changed healthcare financing, promoting the establishment of Accountable Care Organizations (ACOs) to improve care coordination[107]. - Compliance with data privacy and security laws is critical, with potential penalties for violations[112]. Risks and Challenges - The company faces risks related to competition for qualified personnel, particularly in healthcare, which may hinder growth initiatives[149]. - The company may incur significant losses if healthcare service expenses exceed the revenue received from payors under capitation contracts[171]. - The company faces increasing competition from various entities, including Oak Street Health, Astrana Health, and agilon health, which may impact market share and profitability[175]. - Changes in government regulations or private initiatives affecting healthcare delivery could adversely impact the company's revenue[182]. - The company is exposed to risks from competitive developments, including pricing changes and the introduction of new products by competitors[213]. Technology and Innovation - The proprietary P3 Technology/Health Hub integrates clinical and claims data monthly from various sources, allowing for risk stratification and proactive care delivery[58]. - The Provider Portal enables physicians to access risk stratified patient lists and identify care opportunities, improving cost management and patient outcomes[59]. - The Analytic Management Tools platform provides real-time metrics and visualizations to support decision-making and optimize resource utilization across the organization[62]. - The company utilizes AI technologies, which are subject to evolving regulatory frameworks that may impact operations and increase compliance costs[202]. Employee and Talent Management - As of December 31, 2024, the company had approximately 360 full-time employees, with a focus on attracting and retaining skilled talent[83]. - High employee turnover and labor shortages were experienced in 2024, affecting the ability to hire qualified personnel[147]. Financial Liabilities and Assets - As of December 31, 2024, the company had $38.8 million in unrestricted cash and cash equivalents, $154.8 million in outstanding indebtedness, and $255.1 million in unpaid claims[125]. - The net carrying value of other intangible assets was $574.4 million, representing 73% of total assets[142]. - A significant goodwill impairment charge of $1,315.0 million was recorded for the year ended December 31, 2022, due to a decrease in share price[142]. Legal and Audit Risks - The company is subject to various legal proceedings and audits that could result in substantial costs and divert management's attention, adversely affecting its financial condition[206]. - The company may be required to refund amounts received from Medicare or Medicaid as a result of adverse audit findings, which could materially affect its operating results[225]. - Regulatory authorities may assert that the company's arrangements with affiliated entities constitute unlawful practices, necessitating restructuring or termination of these relationships[223].

Group 1 - The conference call is for P3 Health Partners' Fourth Quarter 2024 Earnings [1] - Participants include company executives and analysts from various research firms [1][2] - The call will cover forward-looking statements regarding financial outlook and long-term targets [4] Group 2 - The company emphasizes that forward-looking statements are predictions based on current expectations [4] - There are risks and uncertainties that could lead to actual results differing from expectations [5] - The company will refer to non-GAAP financial measures during the call [5]